Cipla gets EIR from USFDA for Patalganga manufacturing facility
20th Jan 2020

Cipla has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for Patalganga manufacturing facility. The Company has received the EIR, indicating closure of the inspection. USFDA had conducted inspection at Patalganga manufacturing facility from November 4, 2019 to November 13, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.